Links To And Excerpts From “Efficacy of ketamine therapy in the treatment of depression”

In this post, I link to and excerpt from Efficacy of ketamine therapy in the treatment of depression [PubMed Abstract] [Full-Text HTML] [Full-Text PDF]. Indian J Psychiatry. 2019 Sep-Oct;61(5):480-485.

There are 22 similar articles in PubMed Central

Abstract

Background: Severe depressive disorder is among most debilitating condition. Conventional pharmacotherapy usually takes several weeks (usually 4-12 weeks) to improve symptoms. Ketamine is an N-methyl-D aspartate receptor antagonist having rapid action on depressive symptoms.

Objectives: The effect of subanesthetic dose of ketamine was assessed on depressive and anxiety symptoms. Illness severity and improvement were assessed after treatment with ketamine.

Materials and methods: Twenty-five drug-free/naïve patients of the male sex, with severe depression having no previous history of psychotic disorder, head injury, organic disorder, cardiological problem, or substance abuse were admitted for the study. Assessments were made at baseline and injection ketamine hydrochloride was given at a subanesthetic dose of 0.5 mg/kg intravenous bolus after preparation. Assessments were repeated 1 h after the first dose. Six doses were given over 2 weeks and assessments were repeated. Final assessments were made after 1 month of the last dose.

Results: There was a significant improvement in depression, anxiety, and the severity of illness after 2 weeks and 1 month of the last dose of ketamine. Significant improvement at 1 ^st h of the first dose was seen in depression and anxiety and not for illness severity. There were transient adverse effects observed in some patients which subsided within 1 h.

Conclusion: Ketamine has a robust and rapid effect on depression, which was seen immediately after the administration of ketamine and sustained at the end of 1 month.

Keywords: Depression; N–methyl-D aspartate; ketamine hydrochloride.

Cited by

• Sex-Specific Brain Transcriptional Signatures in Human MDD and Their Correlates in Mouse Models of Depression.

  Touchant M, Labonté B.Front Behav Neurosci. 2022 May 3;16:845491. doi: 10.3389/fnbeh.2022.845491. eCollection 2022.PMID: 35592639 Free PMC article. Review.

• Glutamate: The Master Neurotransmitter and Its Implications in Chronic Stress and Mood Disorders.

  Pal MM.Front Hum Neurosci. 2021 Oct 29;15:722323. doi: 10.3389/fnhum.2021.722323. eCollection 2021.PMID: 34776901 Free PMC article. Review.

• Rapid and long-lasting antidepressant-like effects of ketamine and their relationship with the expression of brain enzymes, BDNF, and astrocytes.

  Viana GSB, Vale EMD, Araujo ARA, Coelho NC, Andrade SM, Costa ROD, Aquino PEA, Sousa CNS, Medeiros IS, Vasconcelos SMM, Neves KRT.Braz J Med Biol Res. 2020 Dec 18;54(2):e10107. doi: 10.1590/1414-431X202010107. eCollection 2020.PMID: 33331415 Free PMC article.